Details

Autor(en) / Beteiligte

• Nissen, Steven E
• Tardif, Jean-Claude
• Nicholls, Stephen J
• Revkin, James H
• Shear, Charles L
• Duggan, William T
• Ruzyllo, Witold
• Bachinsky, William B
• Lasala, Gabriel P
• Tuzcu, E. Murat

Titel

Effect of Torcetrapib on the Progression of Coronary Atherosclerosis

Ist Teil von

• The New England journal of medicine, 2007-03, Vol.356 (13), p.1304-1316

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2007

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this 24-month clinical trial, torcetrapib, a cholesteryl ester transfer protein inhibitor, failed to cause regression of coronary atherosclerosis, as seen on intravascular ultrasonography, even though levels of high-density lipoprotein cholesterol were markedly elevated. The drug was also associated with an elevation in blood pressure, and the entire torcetrapib research program has been suspended. Torcetrapib, a cholesteryl ester transfer protein inhibitor, failed to cause regression of coronary atherosclerosis, even though levels of high-density lipoprotein cholesterol were markedly elevated. Epidemiologic studies demonstrate an inverse relationship between levels of high-density lipoprotein (HDL) cholesterol and the incidence of cardiovascular disease. 1 Limited clinical trials have suggested that an increase in HDL cholesterol levels may reduce the progression of coronary atherosclerosis and decrease cardiovascular morbidity. 2 , 3 Cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesteryl ester from HDL cholesterol to low-density lipoprotein (LDL) cholesterol and very-low-density lipoprotein (VLDL) cholesterol. Recently, the administration of the CETP inhibitor torcetrapib has been shown to increase HDL cholesterol levels by more than 50%. 4 However, the effectiveness of CETP inhibition as a strategy for antiatherosclerotic therapy has . . .